home / lobbying / lobbying_activities

lobbying_activities: 2340746

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2340746 54c6cef0-6f8b-4a7e-844a-c837c482fe14 Q3 MCDERMOTT+ LLC 401103287 CAMPAIGN FOR SUSTAINABLE DRUG PRICING 2019 third_quarter PHA Issues relating to prescription drug pricing S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions for Patients Act S. 1224 and H.R. 2374 - Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act S. 440 - Preserving Access to Cost Effective Drugs Act S. 340 and H.R. 965 - CREATES Act S. 1391 and H.R. 2296 - Fair Accountability and Innovative Research Drug Pricing Act H.R. 1520 - Purple Book Continuity Act H.R. 1503 - Orange Book Continuity Act S. 659 - Biologic Patent Transparency Act S. 551 - Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act S. 1209 - Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act H.R. 2113 - Prescription Drug STAR Act H.R. 985 - FAST Generics Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 S. 2543 - Prescription Drug Pricing Reduction Act of 2019 Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2019-10-11T14:31:55.327000-04:00
Powered by Datasette · Queries took 0.356ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API